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Abstract
Background: Human monoclonal antibodies (mAbs) generated as a result of the immune response are likely to
be the most effective therapeutic antibodies, particularly in the case of infectious diseases against which the
immune response is protective.
Human cytomegalovirus (HCMV) is an ubiquitous opportunistic virus that is the most serious pathogenic agent
in transplant patients. The available therapeutic armamentarium (e.g. HCMV hyperimmune globulins or antivirals)
is associated with severe side effects and the emergence of drug-resistant strains; therefore, neutralizing human
mAb may be a decisive alternative in the prevention of primary and re-activated HCMV infections in these
patients.
Results: The purpose of this study was to generate neutralizing mAb against HCMV from the immunological
repertoire of immune donors. To this aim, we designed an efficient technology relying on two discrete and
sequential steps: first, human B-lymphocytes are stimulated with TLR9-agonists and IL-2; second, after both
additives are removed, the cells are infected with EBV. Using this strategy we obtained 29 clones secreting IgG
neutralizing the HCMV infectivity; four among these were further characterized. All of the mAbs neutralize the
infection in different combinations of HCMV strains and target cells, with a potency ~20 fold higher than that of
the HCMV hyperimmune globulins, currently used in transplant recipients. Recombinant human monoclonal IgG1
suitable as a prophylactic or therapeutic tool in clinical applications has been generated.
Conclusion: The technology described has proven to be more reproducible, efficient and rapid than previously
reported techniques, and can be adopted at low overall costs by any cell biology laboratory for the development
of fully human mAbs for immunotherapeutic uses.
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Background
Antibodies constitute the most rapidly growing class of
human therapeutics and the second largest class of drugs
after vaccines [1]. Most of the growing number of antibod-
ies entering the clinical trials are human [2] and are
derived from phage-display technology [3] or from trans-
genic mice that express human immmunoglobulin genes
[4]. However, the best mAbs for clinical applications
derive from natural human antibodies generated as a
result of the in vivo immune response because they i) are
products of the human and not animal repertoire, and ii)
are of human origin, thus minimizing the risks of reactiv-
ity against self-antigens. Lastly, iii) passive immuno-
therapy with human IgG can confer immediate protection
without the side effects linked to the use of chimeric or
humanized mAbs containing animal-derived amino acid
sequences. Furthermore, considerable evidence indicates
that antibodies represent a new, although historically val-
idated, approach to the development of therapies against
bacterial and viral pathogens that causes disease in indi-
viduals with impaired immune response and/or for which
there are few or no available drugs [5-8].
EBV has long been used to immortalize human B-lym-
phocytes in vitro and to isolate human mAb [9-11], but
the method was not routinely embraced due to its poor
efficiency and because the resulting transformed cells are
frequently unstable and fail to grow or secrete IgG. Ago-
nists of Toll receptor 9 (TLR9), e.g., CpG ODN 2006 (syn-
thetic oligodeoxynucleotides that contain
immunostimulatory deoxycytidyl-deoxyguanosine
motifs), have been reported to improve EBV infectivity
and cloning efficiency [12], however, there is no clear con-
sensus as to the best conditions for their use and which
subset of B-lymphocytes should be used. We applied the
EBV immortalization procedure in the presence of differ-
ent amounts of CpG with or without IL-2 to 3 healthy
donors selected on the basis of the high titer of CMV-spe-
cific IgG in the blood and we obtained an immortaliza-
tion efficiency not comparable to that recently reported
[12]. Therefore we re-evaluated all the steps crucial to cell
immortalization, and established an optimized procedure
of isolating human mAbs from the repertoire of immune
donors. The resulting method is highly reproducible,
effective and rapid. Further, it was validated by the suc-
cessful isolation of clones of human B-lymphocytes that
secrete high levels of IgG that bind and neutralize the
human cytomegalovirus (HCMV). HCMV is a ubiquitous
opportunistic virus that infects 50–90% of adult human
populations and persists for the life of the human host
after primary infection. HCMV infection of an immuno-
competent individual generally results in subclinical dis-
ease; by contrast, HCMV infection of
immunocompromised individuals may cause lethal infec-
tions [13]. Indeed, HCMV remains the single most impor-
tant pathogen in hematopoietic stem cell transplantation
[14] as well as, in organ transplantation [15] so that effec-
tive neutralizing mAbs would make a major contribution
to eliminate HCMV in these patients.
Results and discussion
The isolation of fully human mAb from those generated
during the natural human immune response is likely to
identify the most effective therapeutic antibodies [6,16].
Many approaches have been used to generate human mAb
[17], however, an efficient and reproducible process to
isolate human mAb with desired specificity from the nat-
ural repertoire is not available.
Agonists of TLR9 have been reported to improve EBV
infectivity and cloning efficiency [12]. However, it is
known that TLR9 agonists, such as CpG ODN 2006, pro-
tect against a wide range of viral pathogens [18-20]. With
this in mind, we reasoned that the presence of CpG during
the EBV infection might exert negative effects and we
decided to separate activation and EBV infection in two
sequential phases. We developed a technology for raising
human mAbs for clinical applications based on two dis-
crete steps (SEQUENTIAL, Figure 1): first, purified human
B-lymphocytes are treated with CpG2006 and IL-2. Next,
after both additives are removed, the activated cells are
infected with EBV in a distinct step. The new process was
compared to a method using CpG2006 and IL-2 in the
presence of EBV [12] (COMBINED) and a method using
Outline of the procedure for comparing EBV transformation  methods Figure 1
Outline of the procedure for comparing EBV trans-
formation methods. Overview of the procedure for com-
paring the populations of EBV-transformed cells according to 
the SEQUENTIAL, COMBINED, and BASIC methods.BMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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EBV alone (BASIC) (Figure 1). Different experimental set-
tings were compared in pools of cells derived from 5
healthy donors, to minimize donor variability. The results
clearly demonstrated that activation of CD22+  B-lym-
phocytes before EBV exposure leads to improved immor-
talization, as highlighted by the viability of cells following
EBV transformation which is significantly higher than that
obtained with both combined and basic conditions (Fig-
ure 2A). The short-term viability of B lymphocytes immor-
talized following the basic procedure is higher than those
of B lymphocytes treated with the combined procedure.
This is attributable to the polyclonal activation elicited by
EBV itself which is not paralleled by an efficient immortal-
ization. Indeed, it is well documented that exposure of
human B-lymphocytes to EBV results in cell death of a
proportion of cells and that B-lymphocytes are activated
but not immediately immortalized following exposure to
EBV [21-23].
Removal of the activating agents before immortalization
significantly improves growth and viability of CD22+ B-
lymphocytes allowing for a higher proportion of cells to
be immortalized. Indeed, when stimulation and EBV
infection are performed separately rather than simultane-
ously, or with no stimulation at all, the cells exhibit
increased proliferation potential and improved viability.
In contrast, the combined presence of activating agents
and EBV has adverse effects on both cell viability and EBV
infectivity (Figure 2A, B). The negative effects of the COM-
BINED method on viability are surprising, given that
CpG2006 induces robust polyclonal activation and prolif-
eration of B-lymphocytes [24,25] and that these effects are
significantly enhanced by IL-2 [26]. It has been reported
that TLR-9 triggering resulted in higher transformation
rates of B cells infected with EBV [12] but a comparison
between EBV transformation in the presence of CpG2006
and EBV and after sequential exposure of B cells to
CpG2006 and separately to EBV, was not investigated. The
results obtained using different experimental setting on
the same cell population clearly demonstrated that
CpG2006 and IL-2 used in combination with EBV exert
negative effects on cell transformation. It is conceivable
that the detrimental effects are related to the anti-prolifer-
ative activity of anti-viral cytokines induced by CpG2006
[27,28]. Indeed, the significant levels of TLR9 expressed
by resting B-lymphocytes are further up-regulated by
CpG2006 itself. Increased TLR9 expression correlates with
increased responsiveness to the ligand, indicating a posi-
tive feedback loop in which CpG2006 enhances its own
effects [29]. Kinetic studies demonstrated that optimal
concentrations of CpG2006 combined with IL-2 provide
maximal cell stimulation after 2–5 days (data not shown).
These observations are in line with cell-cycle analyses
demonstrating that, in the same time frame, more than
Quantitative and qualitative comparison of different EBV  transformation methods Figure 2
Quantitative and qualitative comparison of different 
EBV transformation methods. A) The B-lymphocyte 
subsets were prepared using the SEQUENTIAL, COMBINED 
or BASIC methods, as outlined in Fig. 1. Ten days after expo-
sure to EBV, samples of each population were compared for 
the total cell number (black bars), and for the number of via-
ble cells (white bars) measured microscopically by trypan 
blue dye exclusion. Data are expressed as % of initial B cells 
exposed to EBV and represent the means ± s.d. of 5 cell 
counts for each condition. Results are representative of two 
independent experiments. P < 0.001: SEQUENTIAL vs. 
COMBINED; BASIC vs. COMBINED (white bars); P < 0.05: 
SEQUENTIAL vs. BASIC (white bars) and SEQUENTIAL vs. 
COMBINED; and BASIC vs. COMBINED (black bars). B) Ten 
days after infection with EBV, the cells prepared by the 
SEQUENTIAL, COMBINED, or BASIC method were ana-
lyzed to identify viable lymphoblasts by propodium iodide (PI) 
exclusion (top panels) and CD23 expression (bottom panels) 
by flow cytometry. For each population of cells, the viable 
lymphoblasts (gated in regions R2, top panels) were defined 
as those with relatively high forward scatter (horizontal axes) 
and negative for PI fluorescence (vertical axes). R2 gated cells 
were then analyzed for CD23 expression. Fluorescence was 
analyzed with a FACSCalibur flow cytometer and CellQuest 
software (Becton Dickinson). Background fluorescence was 
determined with a FITC-labeled, isotype-matched negative 
control mAb. 10,000 events were measured for each condi-
tion.BMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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95% of B cells enter the cell cycle independently from
their memory or naïve phenotype [24,30].
The SEQUENTIAL method does not modify the expres-
sion of CD21, which is the receptor for EBV [31].
The next step was to correlate the efficiency of EBV infec-
tion to the expression of CD23, which is directly upregu-
lated by EBNA2, one of the earliest markers expressed by
EBV-infected B-lymphocytes [32], it is expresses at high
levels on EBV-transformed B cells [33] and its expression
correlates with IgG secretion [34]. The results demon-
strated that CD23 expression (the number of positive cells
and mean fluorescence intensity) is higher on cells
exposed to the polyclonal activators and EBV separately
than on those exposed simultaneously (Figure 2B).
The B-lymphocytes representing the whole repertoire of a
selected donor immortalized with the SEQUENTIAL
method show a significantly higher viability than those
obtained with the COMBINED method, and in conse-
quence are easily clonable by limiting dilution, either in
the presence or in the absence of polyclonal activators,
such as CpG2006 and IL-2. TLR9 expression is increased
after EBV infection. Thus bona fide, the addition of
CpG2006 during the cloning phase enhances cell growth.
However, we observed that cloning efficiency may be
independent of CpG2006 and IL-2 in some donors, sug-
gesting that it is also dependent on the genetic back-
ground or physiological state of the donor. This issue
warrants further investigation. The presence of CpG2006
and IL-2 during the cloning phase may also have practical
relevance for screening procedures. For instance, trace
amounts of CpG2006 completely block HCMV infection
in vitro, hampering screening by functional assays [20].
Moreover, CpG2006 is a potent inducer of cytokines, such
as IL-12 and IFN-γ, potentially interfering with a number
of bioassays [35].
The validity of the SEQUENTIAL method was evaluated
by using it in a project to produce neutralizing human
mAbs against HCMV, a leading cause of morbidity and
mortality in immunocompromised individuals and the
most serious pathogenetic agent in transplant patients
[15,36,37]. In the absence of other therapies such as vac-
cines [38], these patients are treated with antivirals, which
are often associated with considerable side effects and the
emergence of drug-resistant strains. HCMV is also the
leading viral cause of congenital infection associated to
significant birth defects and neurological damage for
which no effective therapies are available before birth
[13,39]. Hyperimmune globulins specific for HCMV are
beneficial in both conditions for the prevention and treat-
ment of these infections [40,41]. Further, transfer of mem-
ory B cells from immune animals to severely
immunodeficient recipients confers long-term protection
from lethal murine CMV infection. This indicates that the
humoral immune response is effective against CMV infec-
tion in the absence of a T cell-mediated response [42].
Natural human mAbs with stronger neutralizing activity
than that of currently available immunoglobulin prepara-
tions may be a decisive alternative in the prevention of
primary and re-activated HCMV infections in immuno-
suppressed patients, or during high-risk pregnancies [43].
Using the SEQUENTIAL method, we obtained natural
antibodies neutralizing HCMV infectivity by immortaliz-
ing B-lymphocytes from a healthy donor (CMV5) and
from a patient recovering from acute HCMV infection
(CMV7). High titers of anti-HCMV-specific IgG coupled
with the virus-neutralizing activity of the sera were the cri-
teria for selecting the two donors from a larger panel
(Table 1). The immortalized B-lymphocytes were cloned
by limiting dilution. After 3 weeks, clusters of cells grow-
ing in wells were appreciable and the IgG concentration in
the clone supernatants was 10–40 μg/ml/106 cells, as
determined by means of an immunoenzymatic method,
measuring IgG concentrations in the media normalized
for cell densities. Clones producing HCMV-specific IgG
were identified by different primary screening assays. In a
first experiment a total of 1,664 clones were tested either
by their binding to specific HCMV envelope glycoprotein
domains (such as those from gB or gH, which have been
shown to induce neutralizing antibodies) [44], or by their
ability to neutralize HCMV infectivity in vitro [45,46]. The
effect on HCMV infectivity was determined by an HCMV
microneutralization assay based on the evaluation of the
ability of clone supernatants to interfere on the infectivity
of HCMV AD169 strain (a laboratory strain from ATCC,
cod. VR-538) in human Embryo Lung Fibroblasts (HELF).
This strategy yielded 44 clones producing mAbs specific
for the gB, and 15 for gH. Nine of these displayed a neu-
tralizing activity of > 40%. Those supernatants that were
negative in the gB and gH ELISAs, or in the neutralization
assay were also screened in an ELISA that detects human
IgG that bind to HCMV virion proteins extract (BEIA-
CMV), and 8 samples were further selected by this screen-
ing assay. In a second experiment, the immortalized B-
lymphocytes were cloned by limiting dilution and after 3
weeks, 324 clones were screened directly for their neutral-
izing activity. Of these, 20 produced IgG with a neutraliz-
ing activity of > 40%, among these, 2 wells were found to
bind gB, while the remaining 18 did not bind in either the
gB or gH domains.
Four clones has been chosen as promising candidates for
future clinical applications on the basis of their intrinsic
characteristics: 10B7 and 8C10 showed a very strong bind-
ing to gB glycoprotein and 1F7 to gH glycoprotein; 26A1
has the strongest neutralizing activity. All clones wereBMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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expanded in the absence of CpG2006, IL-2 and a feeder
layer, and further characterized. MAbs10B7 and 8C10
proved to be specific for the HCMV envelope glycoprotein
gB, mAb 1F7 for the HCMV envelope glycoprotein gH and
mAb 26A1 recognized a viral antigen not yet character-
ized, as inferred from the reactivity on the HCMV virion
proteins extract (Table 2).
All of the antibodies neutralized the infectivity of the
HCMV AD169 laboratory strain in human HELF as well as
that of the VR1814 clinical isolate in human umbilical
vein endothelial cells (HUVEC), indicating that they are
neither strain nor cell-specific. Lastly, none of the anti-
bodies bound the HELF or HUVEC (data not shown). The
specificity of the HCMV neutralizing activity was con-
firmed by the lack of significant neutralization of herpes
simplex virus (HSV)-1 in Vero cells (data not shown).
Clone stability was tested by maintaining the cells for 3
months in serum-free medium without CpG2006 or other
additives, and the mAbs recovered in the supernatant at a
concentration of 20–50 μg/ml. All purified IgG maintained
their neutralizing activity; mAb 26A1 demonstrated a potent
neutralizing capacity, with a calculated inhibitory concentra-
tion 50 (IC50) of 0.92 μg/ml against AD169 in HELF (Fig.
3A), and of 1 μg/ml against VR1814 in HUVEC (Fig. 3B).
The potency of 26A1 against both HCMV strains was ~20
fold higher than the reference anti-HCMV IgG (IC50 of 16 μg/
ml), currently used in transplant recipients. The inhibitory
activity of mAb 26A1 against the whole viral replicative cycle
was confirmed by plaque reduction neutralization assay
(Figure 3C). The mechanism of virus neutralization is sub-
ject of ongoing studies.
The broad and robust neutralizing activity of mAb 26A1
encouraged us to generate recombinant IgG suitable as
prophylactic or therapeutic tools in clinical applications.
To this aim, cells were submitted for 5' RACE PCR ampli-
fication, the PCR products of two amplification reactions
were cloned using a Eco RI restriction site in a sequencing
vector and used for transforming TOP10 E. coli. A single
VH and VL sequence was obtained from each cell culture,
confirming that each original culture was clonal (Figure
4).
The sequences encoding the VH and VL regions of mAb
26A1 were cloned in expression vectors for the expression
of mAb 26A1 variable regions as recombinant IgG1. The
recombinant mAb 26A1 confirmed the neutralizing activ-
ity of the natural mAb 26A1 (Figure 3).
The SEQUENTIAL method is also effective when used
with frozen cells. Indeed, it was possible to select antibod-
ies neutralizing HSV-1 and HSV-2 infectivity from frozen
PBMCs from an HSV and HIV co-infected individual (not
shown).
Neutralizing activity of natural (n) and recombinant (m)  purified 26A1 IgG Figure 3
Neutralizing activity of natural (n) and recombinant 
(m) purified 26A1 IgG. The 26A1 mAb was purified from 
serum-free supernatants by protein A chromatography. The 
neutralizing activity of HCMV infectivity was then tested 
either with the laboratory strain AD169 in HELF (panel A) or 
with the clinical isolate VR1814 in HUVEC (panel B). The 
effect of 26A1 IgG on HCMV infectivity was measured by 
staining the HCMV IEA by indirect immunoperoxidase. Five 
fields (HPF 20×) were counted per well from triplicate wells. 
Percentage of inhibition of viral infectivity was calculated 
using the following formula: [(means ± s.d. of IEA+ nuclei of 
HCMV infected cells – means ± s.d. of IEA+ nuclei of 26A1-
treated HCMV infected cells/means ± s.d. of IEA+ nuclei of 
HCMV infected cells) ×100]. Results represent the means ± 
s.d. of 3 independent experiments. Plaque reduction assay 
(panel C) shows the neutralizing activity of natural and 
recombinant 26A1 mAb against HCMV AD169 (1,000 pfu/
rxn) in HELF. The values were plotted as a function of IgG 
concentration, and the concentrations of IgG required to 
inhibit viral infection by 50% (IC50) were calculated by linear 
regression using GraphPad Prism (v. 4.0) software.
A
%
 
o
f
 
i
n
h
i
b
i
t
i
o
n
mAb ( g/ml)
0 2.5 5.0 7.5 10
0
25
50
75
100
natural mAb 26A1
recombinant mAb 26A1
HCMV AD169 in HELF
C
%
 
o
f
 
i
n
h
i
b
i
t
i
o
n
100
0 2.5 5.0 7.5 10
0
25
50
75
B HCMV VR1814 in HUVEC
mAb ( g/ml)
%
 
o
f
 
i
n
h
i
b
i
t
i
o
n
0 2.5 5.0 7.5 10
0
25
50
75
100
HCMV AD169 in HELF
mAb ( g/ml)
natural mAb 26A1
recombinant mAb 26A1
natural mAb 26A1
recombinant mAb 26A1BMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
Page 6 of 10
(page number not for citation purposes)
Conclusion
In summary, this study provides proof of concept that
good-quality, fully human mAbs with desired specificity
and biological activity can be generated with the
SEQUENTIAL method. The strengths of this approach are:
i) it allows the selection of human monoclonal IgG to a
variety of antigens, from a small sample of fresh or frozen
peripheral blood, ii) it is rapid, iii) screening can be per-
formed using a variety of assays, including functional
assays, iv) the mAbs of interest can be easily produced
from the original clone as recombinant proteins suitable
for clinical applications, and v) the generation of IgG-
secreting polyclonal populations can be considered as a
library of antibody-secreting cells that can be used to
select mAbs with specificities not considered when cells
were immortalized.
The technology described has proven to be more repro-
ducible, efficient and rapid than previously reported tech-
niques, and can be adopted at low overall costs by any cell
biology laboratory for the development of fully human
mAbs for immunotherapeutic uses. It can be applied to
the isolation of natural mAbs from individuals affected by
a variety of diseases, ranging from infectious diseases to
cancer and autoimmune diseases. It allows the isolation
of a large repertoire of human mAbs with desired specifi-
cities to be selected from a small (~8 ml) volume of
peripheral blood, and can be used with either fresh or fro-
zen B-lymphocytes. Moreover, direct cloning by limiting
dilution and robust IgG production allow the generation
of panels of mAbs with different specificities, thus allow-
ing the development of mAb cocktails for immuno-
therapy [47].
Methods
Collection of Blood Samples and Isolation of Mononuclear 
Cells
After informed consent was obtained, peripheral blood
(8–10 ml) was collected from healthy blood donors or
infectious disease patients. Serum was screened for reac-
tivity with HCMV glycoproteins and for HCMV neutraliz-
ing activity. Peripheral blood mononuclear cells (PBMCs)
were purified from heparinized peripheral blood by den-
sity gradient centrifugation on Ficoll/Hypaque (Amer-
sham Pharmacia, Milan, Italy).
Qualitative and quantitative comparison of different EBV 
transformation methods
CD22+ lymphocytes were purified by magnetic selection
(Miltenyi Biotec, Bologna, Italy) from PBMCs pooled from
5 healthy donors, then CD22+cells were divided into three
aliquots that were exposed to different EBV-based methods
for immortalization. For the BASIC process, CD22+/IgG+
lymphocytes were isolated by depletion of IgM+ cells with a
MoFlo® High-Performance Cell Sorter (Dakocytomation,
Glostrup, Denmark) and cultured (106/ml) in 24 well
plates in Iscove's Modified Dulbecco's medium (IMDM)
supplemented with L-glutamine, 100 μg/ml streptomycin
and 100 U/ml penicillin, non-essential amino acids and
10% FBS (complete medium) for 15 h, in the presence of
EBV-containing supernatant (from B95-8 marmoset lym-
phoma cells, ATCC, Washington, DC, cat. no. CRL-1612)
1:1 (v/v) at 37°C and 5% CO2. The cells were then washed
Table 1: Characterization of HCMV Donor Sera
Donor BEIA-CMVa gBb CMV neutralization titerc
CMV5 + + 1:42
CMV6 + - 1:12
CMV7 + + 1:105
CMV8 + - 1:20
CMV9 - - 1:15
a. BEIA CMV ELISA detects human IgG that bind to total protein 
lysates from HCMV virions.
b. gB ELISA detects human IgG that bind to the AD-2 region of the 
HCMV envelope glycoprotein gB.
c. Sera were tested in the HCMV microneutralization assay using the 
AD169 strain and HELF [48]. Numbers indicate dilution of serum 
required for 50% inhibition of HCMV infectivity.
Table 2: Characterization of clones producing neutralizing IgG to HCMV
10B7 1F7 26A1 8C10
Donor CMV5 CMV5 CMV7 CMV7
Doubling Time (days) 44 4 4
IgG Subclass IgG1 IgG1 IgG1 IgG2
BEIA-CMVa -- + +
gB ELISA +- - +
gH ELISA -+ - -
HELF bindingb -- - -
HUVEC bindingb -- - -
HCMV neutralizationc 64.72 ± 11.34 47.23 ± 2.98 86.34 ± 8.15 52.3 ± 13.34
a. Antibodies were tested using the BEIA CMV ELISA assay
b. Antibodies were tested for binding to uninfected HELF and HUVEC by immunohistochemistry.
c. Antibodies were tested using the HCMV microneutralization assay, with the HCMV AD169 strain and HELF. Results are expressed as % of 
inhibition of virus infectivity. Data represent the mean ± s.d. of 3–4 experiments.BMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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and cultured (1.5 × 106/ml) for 10 days in complete
medium in the presence of irradiated (30 Gy) allogeneic
PBMCs (0.5 × 106/well). For the COMBINED process,
CD22+/IgG+ lymphocytes (selected as above mentioned)
were cultured (1.5 × 106/ml) in complete medium with
EBV-containing supernatant 1:1 (v/v), CpG ODN2006 (5'-
TCGTCGTTTTGTCGTTTTGTCGTT-3') (1 μg/ml) (Meta-
bion, Planegg-Martinstried, Germany) and IL-2 (200 U/ml)
(Roche, Milano, Italy), in the presence of irradiated, alloge-
neic PBMCs. For the SEQUENTIAL process, CD22+ lym-
phocytes were cultured (1.5 × 106/ml) for 4 days in
complete medium containing CpG2006 (1 μg/ml) and IL-
2 (200 U/ml), then washed. The IgG+ lymphocytes were
isolated by depletion of IgM+ cells with a MoFlo® High-Per-
formance Cell Sorter (Dakocytomation, Glostrup, Den-
mark), cultured (106/ml) in complete medium with EBV-
containing supernatant 1:1 (v/v) for 15 h, washed and
maintained (1.5 × 106/ml) in complete medium in the
presence of irradiated, allogeneic PBMCs.
The number of viable lymphoblasts was measured micro-
scopically by trypan blue dye exclusion. Where indicated,
the DNA intercalating, fluorescent dye propidium iodide
(PI, Sigma Aldritch) was used with a FACSCalibur flow
cytometer and CellQuest Software (Becton Dickinson,
Franklin Lakes, NJ) to assess cell viability. Viable cells
were defined as those with a high forward and orthogonal
scatter, characteristic of lymphoblasts, and excluding PI.
Analysis of CD23 expression
CD23 expression was measured by direct immunofluores-
cence. Briefly, cells (3 × 105/100 μl) were incubated for 30
Alignment of the DNA (lower case) and protein (upper case) consensus sequence of the heavy and light chains of the human  recombinant 26A1 IgG Figure 4
Alignment of the DNA (lower case) and protein (upper case) consensus sequence of the heavy and light chains 
of the human recombinant 26A1 IgG. The variable regions of heavy chain (VH) and light chain (VL) of mAb 26A1 were 
sequenced according the technology established by Fusion Antibodies Ltd. and described in the Methods section.
26A1 Heavy chain
atgaacatactgtggagcatgctcctgctggtggcagctcccagatgggtcctgtcccag
 M  N  I  L  W  S  M  L  L  L  V  A  A  P  R  W  V  L  S  Q   20 
gtgcagctgcaggagtcgggcccaggactggtgaagccttcacagaccctgtccctcata
 V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q  T  L  S  L  I   40 
tgcactgtctctggtggctccgtcagcagtggtggtgactactggacctggatccgccag
 C  T  V  S  G  G  S  V  S  S  G  G  D  Y  W  T  W  I  R  Q   60 
cacccagggaagggcctggagtggcttgggtacatccattccagtgggaatatcttctac
 H  P  G  K  G  L  E  W  L  G  Y  I  H  S  S  G  N  I  F  Y   80 
aacccgtccctcaagagtcgactgaccttatcaatggacacgtctaagaaccaattcttc
 N  P  S  L  K  S  R  L  T  L  S  M  D  T  S  K  N  Q  F  F  100 
ctgaagttgacctctgtgactgccgcggacacggccgtatattactgtgcgagagtctat
 L  K  L  T  S  V  T  A  A  D  T  A  V  Y  Y  C  A  R  V  Y  120 
cataaggattttgtagtagtaccaggtgctttcccctttgaattctggttcgacccctgg
 H  K  D  F  V  V  V  P  G  A  F  P  F  E  F  W  F  D  P  W  140 
ggccagggaaccctggtcaccgtctcctcaggatccgcctccaccaagggcccatcggtc
 G  Q  G  T  L  V  T  V  S  S  G  S  A  S  T  K  G  P  S  V  160 
ttccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctg
 F  P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  L  G  C  L  180 
gtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagc
 V  K  D  Y  F  P  E  P  V  T  V  S  W  N  S  G  A  L  T  S  200 
ggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg
 G  V  H  T  F  P  A  V  L  Q  S  S  G  L  Y  S  L  S  S  V  220 
gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaag
 V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  C  N  V  N  H  K  240 
cccagcaacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaactcacaca
 P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  K  T  H  T  260 
tgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca
 C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  P  P  280 
aaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggac
 K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  300 
gtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcat
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  320 
aatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgggtggtcagcgtc
 N  A  K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  340 
ctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaac
 L  T  V  L  H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  360 
aaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaa
 K  A  L  P  A  P  I  E  K  T  I  S  K  A  K  G  Q  P  R  E  380 
ccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctg
 P  Q  V  Y  T  L  P  P  S  R  D  E  L  T  K  N  Q  V  S  L  400 
acctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatggg
 T  C  L  V  K  G  F  Y  P  S  D  I  A  V  E  W  E  S  N  G  420 
cagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttc
 Q  P  E  N  N  Y  K  T  T  P  P  V  L  D  S  D  G  S  F  F  440 
ctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc
 L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  G  N  V  F  S  C  460 
tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccg
 S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  S  L  S  P  480 
ggtaaatga
 G  K stop                                                   482
26A1 Light chain
atggcctggaccgttctcctcctcggcctcctctctcactgcacaggttctgtgacctcc
 M  A  W  T  V  L  L  L  G  L  L  S  H  C  T  G  S  V  T  S   20 
tatgtgctgactcagccaccctcggtgtcagtggccccaggacagacggccaggattccc
 Y  V  L  T  Q  P  P  S  V  S  V  A  P  G  Q  T  A  R  I  P   40 
tgtggggggaacgagattggaagtaagagtgtccactggtaccagcagaagccaggccag
 C  G  G  N  E  I  G  S  K  S  V  H  W  Y  Q  Q  K  P  G  Q   60 
gcccctgtgctggtcgtccatgatgacagcgaccggccctcagggatccctgaccgattc
 A  P  V  L  V  V  H  D  D  S  D  R  P  S  G  I  P  D  R  F   80 
tctggctccaactctgggaacacggccaccctgaccatcagcagggtcgaagccggggat
 S  G  S  N  S  G  N  T  A  T  L  T  I  S  R  V  E  A  G  D  100 
gaggccgactattactgtcaggtgtgggatagtggtagtgatcatcatgtggtattcggc
 E  A  D  Y  Y  C  Q  V  W  D  S  G  S  D  H  H  V  V  F  G  120 
ggagggaccaagctgaccgtcctaggtcagcccaaggctgccccctcggtcactctgttc
 G  G  T  K  L  T  V  L  G  Q  P  K  A  A  P  S  V  T  L  F  140 
ccgccctcctctgaggagcttcaagccaacaaggccacactggtgtgtctcataagtgac
 P  P  S  S  E  E  L  Q  A  N  K  A  T  L  V  C  L  I  S  D  160 
ttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtcaaggcggga
 F  Y  P  G  A  V  T  V  A  W  K  A  D  S  S  P  V  K  A  G  180 
gtggagaccaccacaccctccaaacaaagcaacaacaagtacgcggccagcagctatctg
 V  E  T  T  T  P  S  K  Q  S  N  N  K  Y  A  A  S  S  Y  L  200 
agcctgacgcctgagcagtggaagtcccacagaagctacagctgccaggtcacgcatgaa
 S  L  T  P  E  Q  W  K  S  H  R  S  Y  S  C  Q  V  T  H  E  220 
gggagcaccgtggagaagacagtggcccctacagaatgttcatag
 G  S  T  V  E  K  T  V  A  P  T  E  C  S  stop              234 
CDR1
CDR2
CDR3BMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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min at 4°C with anti-human CD23-FITC (Becton Dickin-
son, Milano, Italy). After washing, fluorescence was ana-
lyzed using a FACSCalibur flow cytometer and CellQuest
software. CD23 staining was evaluated only on the viable
lymphoblast population, gated using forward/orthagonal
scatter and PI staining, as described above. Background
staining was determined with a FITC-conjugated isotype-
matched negative control mAb. The number of cells ana-
lyzed was 10,000.
HCMV microneutralization assay
The microneutralization assay was adapted from a previ-
ously reported technique [48]. Briefly, HELF were plated
(2.0–2.5 × 104/well) onto flat-bottom wells of a 96-well
plate in 100 μl of Minimal Essential Medium (MEM)
(Gibco-BRL, Milano, Italy) with 10% FBS, 100 U/ml pen-
icillin and 100 μg/ml streptomycin (growth medium) and
cultured for 24 h at 37°C. Fifty μl of supernatant from B
cell clones (or purified IgG at indicated concentration)
were incubated with the laboratory strain HCMV [AD169;
500 plaque forming units (pfu) in 50 μl of MEM with 5%
FBS] for 1 h at 37°C, then added to the fibroblast monol-
ayers. The plates were then centrifuged at 2,000 g for 30
min and incubated for 90 min at 37°C in 5% CO2.
Growth medium (100 μl) was added and the cultures
incubated for 72 h.
The effect of B cell supernatants (or purified IgG) on
HCMV infectivity was measured by staining the HCMV
Immediate Early Antigens (IEA, IE1+IE2) by indirect
immunoperoxidase. IEA-positive nuclei were counted
under the microscope. B cell supernatants containing
irrelevant IgG antibodies were used as a negative control
and a commercial preparation of human IgG, purified
from the serum of HCMV seropositive patients (Cytotect;
Biotest, Dreieich, Germany), as a positive control, respec-
tively. Positivity was defined as ≥ 40% inhibition of IEA+
cells, compared to negative control wells. HCMV microne-
utralization assays were also performed with the endothe-
liotropic HCMV VR1814, a derivative of a clinical isolate
recovered from a cervical swab of a pregnant woman [49],
and HUVEC, as described above. Experiments were per-
formed with cells at passage 2–6. Plaque reduction assay
was performed as reported [50].
Selected experiments were done with IgG purified on pro-
tein A columns (Biorad, Milano, Italia) from serum-free
supernatants (natural IgG).
ELISA assay for detection of IgG binding to the total 
HCMV virion proteins and to the gB and gH envelope 
glycoproteins (gB ELISA and gH ELISA)
Antibodies were tested using the ELISA assay for detection
of IgG binding to total proteins extract from HCMV viri-
ons (BEIA CMV IgG Quant Kit; Bouty, Milano, Italy)
according to the manufacturer's instructions. The anti-
HCMV recombinant gB IgG ELISA was purchased from
Biotest, AG (Dreieich, Germany) and used according to
the manufacturer's instructions. The ELISA makes use of
the recombinant autologous interstrain fusion antigen
CG3, corresponding to a combination of the gB antigenic
domain 2 (AD2) from HCMV strains AD169 (SwissProt
Acc. No. P06473) and Towne (SwissProt Acc. No.
P13201). The AD2 region contains a site (amino acids
70–81) conserved in different viral strains, that has been
shown to be recognized by neutralizing antibodies
[51,52]. The gB-GST antigen was purchased from Biode-
sign (Saco, ME, USA) and contains a gB immunodomi-
nant region fused to GST that reacts with HCMV-positive
sera. It was used in ELISA assays according to the manu-
facturer's instructions.
The anti-HCMV recombinant gH-specific ELISA was per-
formed using the recombinant gH-GST antigen coated
onto plastic. gH-GST corresponds to an in-frame fusion
between the gH amino terminal region (amino acids 16–
144) from the HCMV strain VR1814 and GST. The amino
terminus of gH contains a linear antibody binding site
between residues 34–43 that is recognized by neutralizing
antibodies [44,53]. The gH gene segment was PCR ampli-
fied from VR1814 DNA with the following primers:
VR1814 gH F: 5'-AGTCATGGATCCCTCCTTAGTCAC-
CTCA-3'; VR1814 gH R: 5'-ACTGATCTCGAGGCCT-
TCAGCTGCTGC-3'. The 400 bp PCR product was then
digested by XhoI and BamHI, the restricted fragment puri-
fied by agarose gel elecrophoresis and cloned into the
pGEX 4T3 expression vector (Amersham) that had been
restricted by XhoI and BamHI and gel purified. The recom-
binant gH-GST fusion protein was then expressed in E. coli
BL21 and purified from the bacterial cell lysate on the
basis of GST affinity.
Sequence of 26A1 IgG and Expression of 26A1 VH/VL 
Sequences
The variable regions of heavy chain (VH) and light chain
(VL) of mAb 26A1 were sequenced according the technol-
ogy established by Fusion Antibodies Ltd. Briefly, frozen
cells pellets (~5 × 104 cells) were used for extracting total
RNA with STAT-60 RNA extraction reagent. cDNA was
produced by reverse transcription with an oligo(d)T
primer. PCR reactions were set up to amplify VH and VL
regions with a mix of IgG- and Igk/λ specific primers,
respectively. The PCR products of two amplification reac-
tions were cloned using a Eco RI restriction site in a
sequencing vector (pCR2.1; Invitrogen) and used for
transforming TOP10 E. coli cells, following the manufac-
turer's instructions. A consensus sequence was deter-
mined from at least ten clones. The resulting DNA
sequences were aligned and translated into protein
sequences enabling the generation of consensus DNA andBMC Biotechnology 2008, 8:85 http://www.biomedcentral.com/1472-6750/8/85
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protein sequence for VH 26A1 and VL 26A1. The VH 26A1
and VL 26A1 protein sequences were compared and
aligned with sequences present in the GenomeQuest,
GeneSeq, and EBI databases. The CDRs characterizing VH
26A1 and VL 26A1 protein sequences were predicted by
the IMGT database [54].
To generate a recombinant IgG1, a consensus 26A1 VH
sequence was amplified by PCR with the following prim-
ers: 5'-TTTTTTAGATCTCACCATGAACATACTGTGGAG-
CATGCTC-3'; 5'-TTTTTTAGATCTTGAGGAGACGGTGA
CCAGGGTTCC-3'. The primers contained a BglII restric-
tion site (underlined) for ligation into the hIgG expres-
sion vector already containing human IgG1 heavy chain
constant domains. The in-house designed bicistronic
mammalian retroviral expression vector pRetMEx (Fusion
Antibodies Ltd. Belfast, Ireland) was a dual promoter vec-
tor allowing expression of both antibody chains. The VH
domain was cloned into the BamH1 site of multiple clon-
ing site (MCS) 1 of the vector.
A complete 26A1 recombinant vector was confirmed by
DNA sequencing. CHO DG44 cells were adapted to
serum-free suspension culture and seeded at 1 × 106 cells/
ml in 125 ml spinner flasks. 300 μg of plasmid DNA was
mixed with 900 μg of linear 25 kDa PEI and used to trans-
fect the cell culture. The medium was harvested after 6
days.
Recombinant mAb was purified with a Protein G column
on an Akta Prime chromatography unit following the
manufacturer's standard programme (recombinant IgG).
Statistical analysis
Values are expressed as means ± sd. Data were analyzed
for significance using a one-way analysis of variance
(ANOVA) with Bonferroni post-test correction for multi-
ple comparisons. Data were considered significant at P <
0.05.  
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